Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer

Molecular Cancer Research

Volumn 5, Issue 5, 2007, Pages 485-496

  Leupold, Jörg H ^a   Asangani, Irfan ^a   Maurer, Gabriele D ^a   Lengyel, Ernst ^b   Post, Stefan ^a   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C JUN; PROTEIN TYROSINE KINASE; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL; CANCER INVASION; CELL CULTURE; CHORIOALLANTOIS; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CHICK EMBRYO; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR AP-2;

EID: 34250321756     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0211     Document Type: Article

References (57)

1. Danø K, Behrendt N, Høyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
2. Andreasen P, Egelund R, Petersen H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
3. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001;12:387-400.
4. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
5. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer and metastasis. Med Res Rev 2001;21:146-70.
6. Fuchs T, Allgayer H. Transcriptional regulation of the urokinase receptor (u-PAR) - a central molecule of invasion and metastasis. Biol Chem 2003;384: 755-61.
7. Lengyel E, Wang H, Stepp E, et al. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. JBC 1996;271:23176-84.
8. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 1999b; 80:1884-91.
9. Allgayer H, Wang H, Wang Y, et al. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2α-related factor. J Biol Chem 1999c;274:4702-14.
10. Frame MC. Newest findings on the oldest oncogene; how activated src docs it. J Cell Sci 2004;117:989-98.
11. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005;331:1-14.
12. Chong Y, Mulhern T, Cheng H. COOH-terminal Src kinase (CSK) and CSK-homologous kinase (CHK-)-endogenous negative regulators of Src-family protein kinases. Growth Factors 2005;23:233-44.
13. Boyd DD, Wang H, Avila H, et al. Combination of an Src kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res 2004;10:1545-55.
14. Iravani S, Mao W, Fu L, et al. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 1998;78:365-71.
15. Allgayer H, Boyd DD, Heiss MM, et al. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002;94: 344-51.
16. Allgayer H, Wang H, Gallick GE, et al. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999a;274: 18428-37.
17. Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res 2001;267:267-76.
18. Ui M, Sonobe MH, Ito T, et al. Biochemical and functional analysis of highly phosphorylated forms of c-Jun protein. FEBS Lett 1998;429:289-94.
19. Htun van der Horst E, Leupold JH, Schubbert R, Ullrich A, Allgayer H. TaqMan®-based quantification of invasive cells in the chick embryo metastasis assay. BioTechniques 2004;37:940-6.
20. Schewe D, Biller T, Maurer G, et al. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2A-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 2005;11:8538-48.
21. Maurer G, Leupold JH, Schewe DM, et al. Induction of urokinase-receptor (u-PAR) gene expression via Src and two different u-PAR-promoter elements: first analysis of in vivo and prognostic relevance in resected colorectal carcinomas. Proc Amer Assoc Cancer Res 2005;46:295 (abstract number 1268).
22. Rivat C, le Floch N, Sabbah M, et al. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003;17:1721-3.
23. Kamada S, Toyoshima K, Akiyama T. Serum-independent phosphorylation of c-Jun and alterations in AP-1 components by transformation with various oncogenes. JBC 1994;269:4565-70.
24. Noti J, Reinemann B, Petrus M. Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Mol Cell Biol 1996;16:2940-50.
25. Xie W, Herschman H. V-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. JBC 1995;270:27622-8.
26. de Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-Jun with ATF-2 and e-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 1995;11 365-76.
27. Merchant J, Iyer GR, Taylor BG, et al. ZBP-89. a Krüppel-like zinc linger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol 1996;16:6644-53.
28. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. JBC 1996;271:28220-8.
29. Virolle T, Monthouel MN, Djabari Z, Ortonne JP, Meneguzzi G, Aberdam D. Three activator protein-1-binding sites bound by the Fra-2zJunD complex cooperate for the regulation of murine laminin a3A (lama3A) promoter activity by transforming growth factor-β JBC 1998;273:17318-25.
30. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM, p21WAF1/CIP1 is up-regulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1-responsive element: involvement of the small GTPase RhoA. Mol Cell Biol 1998;18:6962-70.
31. Maurer GD, Leupold JH, Schewe DM, et al. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 2007;13:1123-32.
32. Funakoshi-Tago M, Tago K, Sonoda Y, Tominaga S, Kasahara T. TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway. Eur J Biochem 2003;270:1257-68.
33. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998;17:213-25.
34. Okan E, Drewett V, Shaw PH, Jones P. The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism. Oncogene 2001;20:1816-24.
35. Cha H, Okada A, Kim KW, Sato H, Seiki M. Identification of cis-acting promoter elements that support expression of membrane-type 1 matrix metalloproteinase (MTI-MMP) in v-src transformed Madin-Darby canine kidney cells. Clin Exp Metastasis 2000;18:675-81.
36. Ishidoh K, Taniguchi S, Kominami E. Egr family member proteins are invoked in the activation of the cathepsin L gene in v-src-transformed cells. Biochem Biophys Res Commun 1997;238:665-9.
37. Bell S, Connolly DC, Maihle NJ, Degeni JL. Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases. Mol Cell Biol 1993;13:5888-97.
38. Wakahara K, Kobayashi H, Yagyu T, et al. Transforming growth factor-β1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells. J Cell Biochem 2004;93:437-53.
39. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005;24:5333-43.
40. Elliott B, Qiao H, Louvard D, Arpin M. Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells. J Cell Biochem 2004;92:16-28.
41. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74.
42. Pongchairerk U, Guan J, Leardkamolkarn V. Focal adhesion kinase and Src phosphorylations in HGF-induccd proliferation and invasion of human cholangiocarcinoma cell line. HuCCA-1. World J Gastroenterol 2005;11: 5845-52.
43. Sridhar S, Miranti C. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006;25:2367-78.
44. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825),on human prostate cancer cells. Cancer Res 2005;65: 91185-9.
45. Summy J, Trevino JG, Lesslie DP, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005;4:1900-11.
46. Zheng R, Yano S, Matsumori Y, et al. SRC tyrosine kinase inhibitor. m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin Exp Metastasis 2005;22:195-204.
47. 1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 2004;23:8238-46.
48. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004;23:4466-76.
49. Suto R, Tominaga K, Mizuguchi H, et al. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Therapy 2004;11:187-93.
50. el Bahassi M, Karyala S, Tomlinson CR, Sartor MA, Medvedovic M, Hennigan RF. Critical regulation of genes for tumor cell migration by AP-1. Clin Exp Metastasis 2004;21:293-304.
51. Dang J, Boyd D, Wang H, et al. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem 1999;264:92-9.
52. Luckow B, Schutz G. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res 1987;15:5490.
53. Gorman C, Moffat L, Howard B. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2: 1055-51.
54. Gorman C, Merlin GT, Willingham MC, et al. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A 1982;79:6777-81.
55. Dikic I, Batzer AG, Blaikie P, et al. She binding to nerve growth factor receptor is mediated by the phosphotyrosine interaction domain. J Biol Chem 1995;270:15125-9.
56. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
57. de la Monte SM, Lahousse SA, Carter J, Wands JR. ATP Luminescence-based motility-invasion assay. BioTechniques 2002;33:98-106.